Isidoros Axiotis from Kardassis lab presented the paper: Murphy et al. The APOE isoforms differentially shape the transcriptomic and epigenomic landscapes of human microglia xenografted into a mouse model of Alzheimer’s disease” Nat Commun. 2025 May 27;16(1):48836.
Konstantina Kapeta from Chroni’s lab presented the paper: Guo et al. Decreased lipidated ApoE-receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes. Cell. 2025 Jan 9;188(1):187-206.
Zouzana Kounoupa from Kardassis’ lab presented the paper: TRPV1 regulates ApoE4-disrupted intracellular homeostasis and decreases synaptic phagocytosis by microglia. Experimental & Molecular Medicine. 2023 55:347-363
Nagia Dedemadi from Chroni’s lab presented the paper: Co-aggregation with Apolipoprotein E modulates the function of Amyloid-β in Alzheimer’s disease. Nat Commun. 2024 Jun 1;15(1):4695.
Maria Kalykaki from Kardassis’ lab presented the paper APOE4/4 is linked to damaging lipid droplets in Alzheimer’s Disease microglia by Haney et al., Nature. 2024 Apr;628(8006):154-161
A new study published in the Journal Nature Medicine by Fortea et al. suggests that homozygosity for the E4 allele of APOE is a new genetic form of Alzheimer’s Disease. These findings warrant the development of novel strategies for treatments and clinical trials. The commentary can be found here
Daphne Georgiadou from Chroni’s lab presented the paper: The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation. Nelson et al., Nature Neurosci. 2023 Dec;26(12):2104-2121.
A recent review published in the Journal Science Translational Medicine focuses on two new anti-amyloidantibodies, lecanemab (Eisai and Biogen) and domanemab (Eli Lilly and Co.) that have received FDA approval for early stages of AD and are currently being tested in clinical trials for pre-clinical AD. The review can be found here: https://www.science.org/doi/10.1126/scitranslmed.adk9993
Evelina Papagrigoraki from Kardassis lab presented the paper: APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes, Blanchard Nature. 2022 Nov;611(7937):769-779.